Safety monitoring of a clinical trial is conducted by an independent physician with relevant expertise. This is accomplished by review of adverse event, immediately after they occur, with timely follow-up through resolution.
Responsibility for data and safety monitoring depends on the phase of the study and may be conducted by sponsor or Contract research organization (CRO) staff or contractor, and/or by the Principal clinical investigator/project manager conducting the study. Regardless of the method used, monitoring must be performed on a regular basis. Oversight of the monitoring activity is the responsibility of the sponsor.
- Clinical monitoring
- Data Monitoring Committee
- Serious adverse event (SAE)
- U.S. Food and Drug Administration (FDA)
- European Medicines Agency
- Ariel E. Quinio, Safety in Clinical Trials: Who is Responsible? International Biopharmaceutical Association:IBPA Publications, 2005
- Carol Rados, Inside Clinical Trials Testing Medical Products in People FDA Consumer magazine, September–October 2003 Issue
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|